ForPatients
by Roche

Solid Tumors

A study to look at how safe different doses of MOXR0916 were for patients with cancer – when combined with one or two other medicines

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Trial Status	Trial Runs In	Trial Identifier
Completed	7 Countries	NCT02410512 2015-000516-18 GO29674

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy; or for which standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for which a clinical trial of an investigational agent is a recognized standard of care. Participants will be enrolled in two stages: a dose-escalation stage and an expansion stage.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT02410512 2015-000516-18 GO29674
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years	No

This clinical trial was done to study a new medicine called, “MOXR0916”, for the treatment of patients with cancer. This study was done to find out if MOXR0916 given with atezolizumab with and without bevacizumab – was safe for patients. Researchers also

wanted to find out if the treatment had any effect on cancer. Two hundred and ninety-eight patients took part in this study at 25 study centers in 7 countries.